En iyi Uveitis podcastleri (2024)

1
Video Short: Marty's Eyes to Modern Medicines: The Future of Thyroid Eye Disease Treatments 1:20

6d ago1:20

1:20

Marty Feldman's iconic eyes were a result of his Thyroid Eye Disease (Graves' ophthalmopathy) and a strabismus which was not corrected properly. Thyroid Eye Disease represents a spectrum of inflammation: https://www.nature.com/articles/s41433-018-0302-1 Our understanding of Thyroid Eye Disease has been slowly increasing over the decades since his r…

1
Update on Regenerative Stem Cell Developments in Glaucoma 51:05

10d ago51:05

51:05

Dr. Thomas Johnson sits down with host Dr. Andrew Pouw to share exciting developments in regenerative stem cell research that may one day cure glaucoma. Learn more about Dr. Johnson's work in a recent presentation he delivered on behalf of the Glaucoma Foundation, and through the Retinal Ganglion Cell Repopulation, Stem Cell Transplantation, and Op…

1
Author Interview: Derin Karacabeyli, 2024 33:27

17d ago33:27

33:27

Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Derin Karacabeyli of Arthritis Research Canada, a rheumatologist and resident in the University of British Columbia Clinician Investigator Program, as they discuss his recent paper ‘Mortality and major adverse cardiovascular events after glucagon-like peptide-1 receptor agon…

1
Webinar Highlights Podcast 2: Evolving Therapeutic Strategies for Psoriatic Diseases 32:56

20d ago32:56

32:56

Webinar Highlights Podcast: Join Professor Christopher Ritchlin, and Professor Philip Mease as they discuss the recent webinar hosted on the IMID Forum ‘Evolving Therapeutic Strategies for Psoriatic Diseases: Not all IL-23s are Created Similar - Part 2’. Watch them discuss key highlights from the webinar including the burden of PsA and PsO, the sim…

1
Retinitis Pigmentosa Treatment and the Role of Vitamin A 29:40

24d ago29:40

29:40

Drs. Jason Comander and Rachel Huckfeldt join host Dr. Ben Young to review management considerations for patients with retinitis pigmentosa (RP). The discussion highlights the winding story of nutritional supplementation recommendations for vitamin A, and the importance of reanalyzing data behind established care patterns. While the latest findings…

1
PsA Podcast: Bimekizumab: Efficacy, safety, and effectiveness in PsA 21:04

1M ago21:04

21:04

Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. This month, the conversation covered a matching-adjusted indirect comparison (MAIC) to assess the comparative efficacy of bimekizumab and risankizumab in patients with psoriatic arthritis over 52 weeks, and a post hoc analysis invest…

1
Semaglutide and NAION 13:41

1M ago13:41

13:41

Dr. Peter Quiros joins host Dr. Amanda Redfern to discuss the recent JAMA Ophthalmology article "The Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide," the first study to report a possible association between semaglutide (Wegovy, Ozempic, Novo Nordisk) and nonarteritic anterior ischemic optic neuropathy (NA…

1
Discussing RA: Long-term safety and efficacy of upadacitinib in SELECT trials 19:24

1M ago19:24

19:24

Join Professor Iain McInnes and Professors Hideto Kameda and Rieke Alten for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA. In this episode, they discuss two papers which investigate the long-term efficacy and safety of upadacitinib in the SELECT trials.…

1
Update on Sustainability in Ophthalmology 35:51

2M ago35:51

35:51

Host Dr. Andrew Pouw welcomes Drs. Aakriti Shukla, Mahsaw Mansoor, and Alan Robin to discuss the latest sustainability initiatives in the ophthalmic OR and clinic that reduce waste, economic costs, and environmental impact. The participants gratefully acknowledge the joint support of the American Academy of Ophthalmology and the American Society of…

1
Discussing AxSpA: Incidence of uveitis following bimekizumab treatment 24:11

2M ago24:11

24:11

Join us for the latest axSpA podcast brought to you by the Immune-Mediated Inflammatory Disease Forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar, and Xenofon Baraliakos to discuss a recent study on the incidence of uveitis in patients with axSpA that were treated with bimekizumab.…

1
Ocular Oncology Clinical Trial Update 31:13

2M ago31:13

31:13

Drs. Maura Di Nicola and Basil Williams join host Dr. Jay Sridhar to discuss the latest ongoing ocular oncology clinical trials for the treatment of uveal melanoma and associated complications of radiation therapy. Their review begins with the DRCR Retina Network’s Protocol AL, which is studying the use of anti-VEGF agents or corticosteroids to red…

1
Author Interview: Professor Laura Andreoli, 2024 44:09

2M ago44:09

44:09

Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Laura Andreoli, a Professor of Rheumatology at the University of Brescia, as they discuss her recent paper ‘The outcomes of children born to mothers with autoimmune rheumatic diseases’, published in The Lancet. Rheumatology on 11th June 2024.…

1
Discussing RA: Neutrophil-to-lymphocyte ratio and treatment response to filgotinib 16:05

2M ago16:05

16:05

Join Professor Iain McInnes and Professors Hideto Kameda and Peter Nash for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA. In this episode, they discuss a paper that investigated whether the baseline neutrophil-to-lymphocyte ratio had an effect on the treatment respons…

1
Discussing RA: February 2024 10:17

3M ago10:17

10:17

Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest information and data in rheumatology. In this episode, he discusses two papers that show the long-term safety and efficacy of JAK inhibitors, both of which have a study period of 6.5 years. In our first paper, Roberto …

1
Discussing AxSpA: Bimekizumab in AxSpA & Secukinumab Patient Clustering 26:26

3M ago26:26

26:26

Join us for the latest axSpA podcast brought to you by the CSF! This month Dr Sofia Ramiro, consultant rheumatologist and senior researcher at Leiden University Medical Centre and Zuyderland Medical Centre, is joined once again by experts with a wealth of clinical knowledge. Joining her is Hideto Kameda, Professor of Internal Medicine at Toho Unive…

1
Discussing PsA: Secukinumab & The Effect of Sex on the Long-Term Persistence of Targeted Therapies 30:33

3M ago30:33

30:33

Join Professors Peter Nash, Philip Mease, Frank Behrens, and Laura Coates as they discuss the top publications in the world of PsA. They discuss two highly relevant topics in the field, namely the effect of sex on the long-term persistence of targeted therapies, as well as the impact of secukinumab on synovitis and enthesitis.…

1
Discussing AxSpA: Long-Term Outcomes of Secukinumab & JAKis in Clinical Practice 25:05

3M ago25:05

25:05

Join us for the latest axSpA podcast brought to you by the Immune-mediated Inflammatory Disease forum! This month Dr Sofia Ramiro is joined by Professors Hideto Kameda and Xenofon Baraliakos to discuss the long-term impact of secukinumab treatment on bone-related outcomes and BTMs in r-AxSpA patients over two years. Our faculty then move on to disc…

1
Discussing RA: January 2024 9:43

3M ago9:43

9:43

Join Professor Iain McInnes for the first episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest information and data in rheumatology.In this episode, he discusses two papers that aimed to advise on treatment of rheumatic diseases in a real-world setting. In our first paper, Emma Dures and her colleagues compiled t…

1
Discussing AxSpA: Upadacitinib in nr-axSpA and certolizumab pegol by baseline MRI and CRP status 22:14

3M ago22:14

22:14

Join us for the latest axSpA podcast brought to you by the Immune- ediated Inflammatory Disease Forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda and Xenofon Baraliakos to discuss the results of a Phase 3 trial on upadacitinib in nr-axSpA and the clinical outcomes of certolizumab pegol treatment in nr-axSpA stratified by base…

1
Discussing PsA: Clinical Response to Guselkumab & Sequential Lines of b/tsDMARDs 32:10

3M ago32:10

32:10

Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. They discuss two highly relevant topics in the field, including the clinical response to guselkumab and the research surrounding sequential lines of b/tsDMARDs.The Immune-Mediated Inflammatory Disease Forum tarafından oluşturuldu

1
Discussing AxSpA: Risk of Uveitis with Different bDMARDs & PROs following Secukinumab Treatment 32:38

3M ago32:38

32:38

Join us for the latest axSpA podcast brought to you by the Immune-mediated Inflammatory Disease forum! This month Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar and Xenofon Baraliakos to discuss the risk of acute anterior uveitis across different bDMARDs in patients with AS. Our faculty then move on to discuss another publicati…

1
Discussing RA: March 2024 8:39

3M ago8:39

8:39

Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest information and data in rheumatology. In this episode, he discusses two papers that that add to the knowledge of common treatments relating to RA. In our first paper, Juergen Rech and colleagues present the results of …

1
Discussing PsA: Long-term safety of ixekizumab & bimekizumab treatment in a TNFi-IR population 38:13

3M ago38:13

38:13

Join Professors Peter Nash, Philip Mease, Frank Behrens, and Laura Coates as they discuss the top publications in the world of PsA. They discuss two highly relevant topics in the field, including the long-term safety of ixekizumab as well as bimekizumab treatment in a TNFi-IR population.The Immune-Mediated Inflammatory Disease Forum tarafından oluşturuldu

1
Discussing AxSpA: Secukinumab retention over time & sacroiliac joint improvements between DMARDs 33:01

3M ago33:01

33:01

Join us for the latest axSpA podcast brought to you by the Immune-mediated Inflammatory Disease forum! This month Dr Sofia Ramiro is joined by Professors Hideto Kameda and Atul Deodhar to discuss the retention rate of secukinumab over two different time periods. Our faculty then move on to discuss another publication, which compares the improvement…

1
Discussing PsA: 2023 EULAR recommendations and improvements in PROs with deucravacitinib 28:33

3M ago28:33

28:33

Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. This month, they focus on the updated 2023 EULAR recommendations for PsA and the improvement of PROs reported in a Phase 2 trial with deucravacitinib.The Immune-Mediated Inflammatory Disease Forum tarafından oluşturuldu

1
Discussing AxSpA: Long-term etanercept response & real-world effectiveness of tofacitinib & adalimumab 29:48

3M ago29:48

29:48

Join us for the latest axSpA podcast brought to you by the Immune-mediated Inflammatory Disease forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar and Xenofon Baraliakos to discuss the long-term etanercept response in patients with radiographic axSpA and the comparison of tofacitinib and adalimumab in a real-worl…

1
IMID Author Interview: Dr Blanca Hernández-Cruz, 2024 33:50

3M ago33:50

33:50

Join Professor Peter Nash from the Griffith University in Brisbane, and Blanca Hernández-Cruz, a rheumatologist at Virgen Macarena University Hospital in Seville, as they discuss her recent paper ‘Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic…

1
Discussing PsA: Guselkumab and analysis of genetic markers 25:46

3M ago25:46

25:46

Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. This month, the conversation covered the post hoc analysis of PsA patients receiving guselkumab, focusing on disease control across domains and patient characteristics, and a systematic review and meta-analysis on genetic markers and…

1
Discussing PsA: Bimekizumab therapy in PsA 29:49

3M ago29:49

29:49

Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. This month, they focus on the latest publication by Su, et al. and discuss the latest in bimekizumab therapy in PsA.The Immune-Mediated Inflammatory Disease Forum tarafından oluşturuldu

1
Stickler Syndrome and Preventive Treatment 33:06

3M ago33:06

33:06

Drs. Emmanuel Chang and Eric Nudleman join host Dr. Ben Young to review Stickler syndrome, when to suspect, and how to diagnose this condition that can lead to significant systemic manifestations and severe vision loss. The panel also discusses the role and evidence for prophylactic treatments to reduce the rate of retinal detachment, which can occ…

1
Author Interview: Dr Adam Goldman, 2024 21:07

3M ago21:07

21:07

Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Adam Goldman, an epidemiology researcher at The Chaim Sheba Medical Center in Tel-Hashomer, and an epidemiology researcher and lecturer at Tel-Aviv University, as they discuss his recent paper ‘Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK i…

1
Eye Drop Waste in Ophthalmology Clinics 23:22

3M ago23:22

23:22

Host Dr. Jay Sridhar welcomes Dr. Gareth Lema to discuss his group's recent study published in Ophthalmology that quantified the amount of eye drop waste in ophthalmic clinics and the implications for practice. When handled appropriately, argues Dr. Lema, eye drops can be used until the FDA-regulated expiration date, and thus help reduce both their…

1
Author Interview: Professor Daniel Blockmans, 2024 26:44

3M ago26:44

26:44

Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Daniel Blockmans, from the Department of Internal Medicine at the University Hospitals Leuven, as they discuss his recent paper ‘Efficacy and safety of upadacitinib in patients with giant cell arteritis (SELECT-GCA): A double-blind, randomized controlled Phase 3 trial…

1
Discussing RA: July 2024 23:23

3M ago23:23

23:23

Join Professor Iain McInnes and guest Professor Maurizio Cutolo for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA. In this episode, two papers that cover important topics in rheumatology are highlighted: the first paper presents the 5-year efficacy and safety results o…

1
Medical Mistakes and What Doctors Can Learn From Pilots 33:21

4M ago33:21

33:21

Dr. Tamara Fountain joins host Dr. Ben Young to discuss strategies to avoid medical mistakes, how to recognize cognitive biases that can lead to diagnostic error, and what we can learn from the airline industry to improve patient safety. For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.…

1
G2211 Add-On Code and the Patient–Physician Relationship 27:32

4M ago27:32

27:32

The Centers for Medicare and Medicaid Services (CMS) created the new G2211 add-on code to address the resource cost and effort to build patient relationships with those impacted by chronic and complex conditions. Use of this new add-on code is dependent on ophthalmologists building strong long-term relationships with patients to benefit their longi…

1
Discussing RA: June 2024 25:59

4M ago25:59

25:59

Join Professors Iain McInnes, Peter Nash, and Maurizio Cutolo for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA. In this episode they discuss two papers, one that investigated the long-term safety of filgotinib in moderate-to-severe RA, and the other a postmarketing an…

1
EULAR 2024 Review Podcast 36:38

4M ago36:38

36:38

Join Dr Sofia Ramiro, Professor Rieke Alten, and Associate Professor Laura Coates as they review their top sessions in RA, PsA, and axSpA from EULAR 2024, providing insight into how these data will shape clinical practice going forward.The Immune-Mediated Inflammatory Disease Forum tarafından oluşturuldu

1
EULAR 2024 Highlights: Day 4 2:44

4M ago2:44

2:44

Join Dr Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 1 of EULAR 2024 (Saturday, June 15).The Immune-Mediated Inflammatory Disease Forum tarafından oluşturuldu

1
EULAR 2024 Highlights: Day 3 4:25

5M ago4:25

4:25

Join Dr Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 3 of EULAR 2024 (Friday, June 14).The Immune-Mediated Inflammatory Disease Forum tarafından oluşturuldu

1
Spaceflight-Associated Neuro-Ocular Syndrome (SANS) 23:37

5M ago23:37

23:37

Spaceflight-associated neuro-ocular syndrome (SANS) is a constellation of findings that often present in astronauts who have undergone long-duration space flight in microgravity environments. Astronauts with SANS may have disc edema, choroidal folds, cotton wool spots, nerve fiber layer thickening on OCT, globe flattening, and hyperopic shift. In t…

1
EULAR 2024 Highlights: Day 2 4:00

5M ago4:00

4:00

Join Dr Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 2 of EULAR 2024 (Thursday, June 13).The Immune-Mediated Inflammatory Disease Forum tarafından oluşturuldu

1
EULAR 2024 Highlights: Day 1 5:09

5M ago5:09

5:09

Join Dr Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 1 of EULAR 2024 (Wednesday, June 12).The Immune-Mediated Inflammatory Disease Forum tarafından oluşturuldu

1
EULAR 2024 Preview Podcast 14:00

5M ago14:00

14:00

Join Dr Sofia Ramiro, Professor Rieke Alten, and Associate Professor Laura Coates as they guide you through their top selections in RA, PsA, and axSpA at EULAR 2024, so that you can better plan your time at what will be a busy and exciting congress.The Immune-Mediated Inflammatory Disease Forum tarafından oluşturuldu

1
Discussing RA: May 2024 30:08

5M ago30:08

30:08

Join Professor Iain McInnes and guests Professor Janet Pope and Dr Sofia Ramiro for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest information and data in RA. In this episode, he discusses two papers that investigated the long-term safety of JAK inhibitors from Phase 3 trials. In our first paper,…

1
The Impact of Declining Reimbursements for Retinal Procedures 26:41

5M ago26:41

26:41

Episode Description Drs. Avni Finn and Yoshi Yonekawa join host Dr. Jay Sridhar to discuss the current state of retinal reimbursements and the impact that the cost of certain diagnostic and surgical procedures is having on the delivery of patient care. For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.…

1
Retinal Artery Occlusions: To tPA or Not to tPA? 35:45

5M ago35:45

35:45

With increasing awareness that a retinal artery occlusion (RAO) is a type of stroke, ophthalmologists must be able to plan the next steps of care when an RAO is identified on exam. Drs. Amanda Henderson and Michael Carper join host Dr. Amanda Redfern to guide us through their recommendations and various tricky scenarios, notably whether or not to a…

1
IMID Author Interview: Dorthe Berthelsen, 2024 23:26

6M ago23:26

23:26

Join Professor Peter Nash from the Griffith University in Brisbane, and Dorthe Berthelsen, a PhD student and physiotherapist at the Parker Institute in Copenhagen and at the University of Southern Denmark, as they discuss her recent paper ‘“I couldn't carry on taking a drug like that”: A qualitative study of patient perspectives on side effects fro…

1
Webinar Highlights Podcast: Evolving Therapeutic Strategies for Psoriatic Diseases 29:42

6M ago29:42

29:42

Webinar Highlights Podcast: Join Professor Iain McInnes and Associate Professor Laura Coates on the Immune-Mediated Inflammatory Disease Forum in their discussion on the recent webinar “Evolving Therapeutic Strategies for Psoriatic Diseases: Not all IL-23s are Created Similar”. Watch them discuss key highlights from the webinar including the burden…

1
IMID Author Interview: Dr Jake Weddell, 2024 21:01

6M ago21:01

21:01

Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Jake Weddell, an academic rheumatology trainee at Leeds Teaching Hospitals NHS Trust, as they discuss his recent paper ‘Real-world experience of IL-17Ai drug survival in a large cohort of axial spondyloarthritis and psoriatic arthritis.’…

Dinlemeye Değer Podcast'ler

Uveitis Podcastleri

Dinlemeye Değer Podcast'ler

Hızlı referans rehberi